Parr Mcknight Wealth Management Group LLC Buys New Stake in Sanofi (NASDAQ:SNY)

Parr Mcknight Wealth Management Group LLC purchased a new position in shares of Sanofi (NASDAQ:SNY - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 32,646 shares of the company's stock, valued at approximately $1,574,000.

A number of other large investors also recently added to or reduced their stakes in the company. WCG Wealth Advisors LLC lifted its stake in Sanofi by 4.6% during the fourth quarter. WCG Wealth Advisors LLC now owns 36,034 shares of the company's stock worth $1,738,000 after purchasing an additional 1,578 shares in the last quarter. Vise Technologies Inc. raised its stake in shares of Sanofi by 3.0% in the fourth quarter. Vise Technologies Inc. now owns 25,484 shares of the company's stock valued at $1,229,000 after acquiring an additional 754 shares in the last quarter. Focus Partners Advisor Solutions LLC acquired a new stake in shares of Sanofi in the fourth quarter valued at $502,000. Waverly Advisors LLC raised its stake in shares of Sanofi by 71.5% in the fourth quarter. Waverly Advisors LLC now owns 9,790 shares of the company's stock valued at $472,000 after acquiring an additional 4,082 shares in the last quarter. Finally, Zimmer Partners LP raised its stake in shares of Sanofi by 21.3% in the fourth quarter. Zimmer Partners LP now owns 488,300 shares of the company's stock valued at $23,551,000 after acquiring an additional 85,800 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Performance

Shares of NASDAQ SNY traded down $0.40 during midday trading on Wednesday, reaching $51.99. 3,469,024 shares of the company were exchanged, compared to its average volume of 2,381,044. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. Sanofi has a 1 year low of $45.80 and a 1 year high of $60.12. The stock has a fifty day simple moving average of $52.54 and a 200 day simple moving average of $51.90. The stock has a market cap of $131.34 billion, a P/E ratio of 20.88, a PEG ratio of 1.01 and a beta of 0.55.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. The firm had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The firm's revenue was down 11.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.78 earnings per share. On average, research analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be given a dividend of $2.0369 per share. This is an increase from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. The ex-dividend date is Friday, May 9th. Sanofi's payout ratio is currently 57.14%.

Analyst Ratings Changes

Several analysts have recently issued reports on SNY shares. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. BNP Paribas started coverage on Sanofi in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective on the stock. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. The Goldman Sachs Group started coverage on Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective on the stock. Finally, Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $63.33.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.